Status:
COMPLETED
SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms
Lead Sponsor:
Shire
Conditions:
ADHD
Eligibility:
All Genders
6-12 years
Phase:
PHASE3
Brief Summary
To assess efficacy and safety of SPD503(guanfacine hydrochloride) in subjects with ADHD and oppositional symptoms.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Healthy subjects with ADHD and oppositional symptoms
- ADHD-RS\>=24
- CGI \>=4
- T-score of Opp subscale CPRS-R:L \>=65
- Normal ECG and BP
- \>= 55 lbs
Exclusion
Key Trial Info
Start Date :
December 4 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 4 2008
Estimated Enrollment :
217 Patients enrolled
Trial Details
Trial ID
NCT00367835
Start Date
December 4 2006
End Date
January 4 2008
Last Update
June 14 2021
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
HOPE Research Institute
Phoenix, Arizona, United States, 85050
2
Valley Clinical Research
El Centro, California, United States, 92243
3
Peninsula Research Associates Inc
Rolling Hills Estates, California, United States, 90274
4
Sarkis Clinical Trials
Gainesville, Florida, United States, 32607